Related Experiment Videos
Clinical implications of increased expression of CD40L in patients with acute coronary syndromes
Jinchuan Yan1, Zonggui Wu, Zuo Huang
1Department of Cardiology, Chang Zheng Hospital, Second Military Medical University, Shanghai 200003, China.
Insights
Soluble CD40 ligand (sCD40L) levels are elevated in patients with acute coronary syndromes (ACS), indicating its potential as a prognostic marker for coronary disease activity.
Area of Science:
- Cardiovascular Medicine
- Immunology
- Biomarkers
Background:
- Acute coronary syndromes (ACS) represent a spectrum of clinical conditions including unstable angina and myocardial infarction.
- CD40 ligand (CD40L) plays a role in inflammatory and thrombotic processes relevant to atherosclerosis.
Purpose of the Study:
- To investigate the clinical implications of CD40L expression in monocytes and serum levels of soluble CD40L (sCD40L) in patients with ACS.
- To assess the relationship between these markers and disease severity and activity.
Main Methods:
- Flow cytometry was used to analyze CD40L expression on monocytes.
- Enzyme-linked immunosorbent assay (ELISA) measured serum sCD40L levels.
- Patients included controls, stable angina (SA), unstable angina (UA), and acute myocardial infarction (AMI) groups.
Main Results:
- Monocyte CD40L expression and serum sCD40L levels were significantly higher in UA and AMI patients compared to SA patients and controls.
- sCD40L levels peaked at 24 hours post-AMI and increased markedly after percutaneous transluminal coronary angioplasty (PTCA).
- Monocyte CD40L expression did not differ before and after PTCA.
Conclusions:
- Elevated serum sCD40L levels may serve as a reliable prognostic indicator for ACS.
- sCD40L could represent a valuable marker for assessing coronary disease activity.
Objective:
To investigate clinical implications of expression of CD40L in monocytes and changes in serum soluble CD40L in patients with acute coronary syndromes (ACS).
Methods:
Sixteen control and 56 patients, including 24 with stable angina (SA), 20 with unstable angina (UA) and 12 with acute myocardial infarction (AMI) enrolled in this study. Expression of CD40L in monocytes was analyzed by flow cytometry and sCD40L levels were measured by ELISA.
Results:
Expression of CD40L in monocytes and serum levels of sCD40L in UA and AMI patients were higher than in SA patients and controls. In patients with AMI, sCD40L levels showed no significant increase when compared to patients with UA, while AMI patients had a peak level of sCD40L at 24 hours after AMI. PTCA induced a marked rise in sCD40L levels in all patients, while CD40L expression in monocytes showed no difference between patients with PTCA, before and after.
Conclusion:
Enhanced level of serum sCD40L may be a reliable prognostic indicator for ACS and may represent a marker of coronary disease activity.
Related Concept Videos
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Coronary Artery Disease I: Introduction
Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease IV: Preventive Measures
Acute Coronary Syndrome I: Introduction
Acute Coronary Syndrome III: Diagnostic Studies